The Histologic Effect of Intraventricular Injection of Metrizamide

Auer, Roland N.; Fox, Allan J.; Kaufmann, J. C. E.

doi:10.1001/archneur.1982.00510130062018

Cited by 14 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experimental studies in animal models have shown that numerous factors from the polymorphonuclear leukocytes are either released or generated and may produce profound pharmacolog ic effects. 7,18,42,55,57,68,71,74,98,114,126,131,136,137,[141][142][143]157,185,202 Similarly, platelets undergo certain transformations, releasing pharmacologically active substances, as depicted in Figure 24. 27,148 It is also known that the activation of mast cells by contrast agents may result in the generation of platelet acti vating factor, which is generally formed during ana phylactoid reactions.…”

Section: Fig 23 Reactions To Contrast Media and Their Manage Mentmentioning

confidence: 99%

Molecular Markers of Contrast Media-Induced Adverse Reactions

Fareed¹,

Moncada²,

Messmore³

et al. 1984

Semin Thromb Hemost

View full text Add to dashboard Cite

Currently used routine laboratory screening methods are not reliable in the prediction of contrast media-related adverse reactions. Cost-effective laboratory methods for various molecular markers of pathophysiologic activation have now become available. In vitro activation tests in high-risk patients may prove to be useful in the prediction of contrast-induced activation of various adverse reactions. If prior clinical evaluation of a patient suggests an ongoing pathologic process, profiling of the following molecular markers may prove to be useful and helpful in avoiding contrast-induced adverse reactions: Fibrinopeptide A, platelet factor 4, thromboxane B2, 5-HETE, physiologic inhibitors of proteases, B beta 15-42 related peptides, bradykinin/kininogen, and anaphylactozins. In patients suspected of reacting to contrast agents, a small dose of 1 to 5 ml can be injected as a bolus and molecular marker profiling on blood drawn after the infusion may prove to be useful screening tests. Additional clinical studies are needed to prove this. However, this screening test should be performed with extreme caution, since some of the patients are known to react to as little as 1 ml dose. The safety of newly developed nonionic contrast agents can be readily assessed by profiling various molecular markers of adverse reactions, which provide a more reliable and quantitative assessment of contrast-induced adverse reactions. Based on molecular marker profiling, various prophylactic agents can be given to high-risk patients to avoid contrast-induced adverse reactions.

show abstract

Section: Fig 23 Reactions To Contrast Media and Their Manage Mentmentioning

confidence: 99%

Molecular Markers of Contrast Media-Induced Adverse Reactions

Fareed¹,

Moncada²,

Messmore³

et al. 1984

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Inflammation and arachnoiditis have been reported in animal models, as well as in human beings. [20][21][22] In a study involving monkeys, minimal inflammation and fibrosis were noted after intrathecal injection of metrizamide (300 mg iodine/ ml), 20 In another study involving rabbits, leukocytic infiltration was found histologically after intrathecal injection of metrizamide (300 mg iodine/ml)." This was severe at one week and resolved by the end of three weeks.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of CSF Rhinorrhea by Computerized Tomography with Metrizamide

Chow¹,

Goodman²,

Mafee³

1989

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

This study evaluates the ability of metrizamide computerized tomographic cisternography (MCTC) to delineate the site of leakage in patients with cerebrospinal fluid (CSF) rhinorrhea. From 1981 to 1986, thirteen patients were examined by MCTC to localize the site of CSF leakage. A total of 17 studies were performed. Thirteen scans (76%) identified the site of CSF leakage. Nine of these scans were confirmed surgically. The other four scans were performed on patients who refused surgery. Of the 15 scans in patients with active CSF leaks, 13 (87%) were positive. Of the two patients with inactive CSF leaks, neither was positive. One patient is presented in whom MCTC was both diagnostic and therapeutic. In conclusion, MCTC has a high success rate in localizing the site of active CSF leaks.

show abstract